An Extension Study of Eltrombopag in Pediatric Patients With Chronic Immune (Idiopathic) Thrombocytopenia Purpura (ITP)
Phase of Trial: Phase III
Latest Information Update: 17 Nov 2017
At a glance
- Drugs Eltrombopag (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Adverse reactions; Registrational
- Sponsors GlaxoSmithKline; Novartis
- 27 Jul 2017 Status changed from recruiting to completed.
- 13 Jun 2017 Planned End Date changed from 19 Apr 2019 to 1 Jul 2017.
- 13 Jun 2017 Planned primary completion date changed from 19 Apr 2019 to 1 Jul 2017.